Fairmount Funds Management LLC 13F holdings, Q3 2025
Holdings as of September 30, 2025 · filings on SEC EDGAR · latest filing →
Fairmount Funds Management LLC disclosed 17 US equity positions worth $1.1bn in its Q3 2025 13F filing. The largest position was DNTH at 11.7% of the reported book, followed by COGT and AXSM. Against the Q2 2025 filing, it opened 1 new position, added to 3 and reduced 0 among the top 17 holdings.
What did Fairmount Funds Management LLC own in Q3 2025? Top 17 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2025 |
|---|---|---|---|---|---|---|---|
| 1 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 11.7% | $130.1m | 3,307,191 | 22% | added |
| 2 | COGT COGENT BIOSCIENCES INC | Healthcare | 11.6% | $129.3m | 9,003,418 | 45% | added |
| 3 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 8.9% | $99.0m | 815,176 | 0% | held |
| 4 | APGE APOGEE THERAPEUTICS INC | Healthcare | 7.3% | $81.4m | 2,048,647 | 0% | held |
| 5 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 6.8% | $76.0m | 3,711,444 | 0% | held |
| 6 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 6.7% | $74.7m | 3,459,913 | 0% | held |
| 7 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 6.4% | $71.3m | 3,705,262 | 10% | added |
| 8 | KINIKSA PHARMACEUTICALS INTL | 6.2% | $68.8m | 1,772,839 | 0% | held | |
| 9 | SRRK SCHOLAR ROCK HLDG CORP | Healthcare | 6.1% | $67.9m | 1,824,031 | 0% | held |
| 10 | SYRE SPYRE THERAPEUTICS INC | 6.1% | $67.3m | 4,018,101 | 0% | held | |
| 11 | NUVALENT INC | 5.7% | $62.9m | 727,563 | 0% | held | |
| 12 | ABVX ABIVAX SA | 5.4% | $60.6m | 713,434 | – | new | |
| 13 | ZBIO ZENAS BIOPHARMA INC | 3.8% | $42.0m | 1,892,806 | 0% | held | |
| 14 | JBIO JADE BIOSCIENCES INC | 2.5% | $27.8m | 3,220,368 | 0% | held | |
| 15 | CATBUSD ASTRIA THERAPEUTICS INC | 2.3% | $25.9m | 3,554,129 | 0% | held | |
| 16 | CBIO CRESCENT BIOPHARMA INC. | 1.5% | $16.5m | 1,387,866 | 0% | held | |
| 17 | IKT INHIBIKASE THERAPEUTICS INC | 0.9% | $9.9m | 6,125,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.